Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 40Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 29Urinary Bladder Neoplasms 15Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Pancreatic Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Ovarian Neoplasms 11Sarcoma 10Hodgkin Disease 10Glioblastoma 10Carcinoma, Transitional Cell 10Rectal Neoplasms 9Triple Negative Breast Neoplasms 8Prostatic Neoplasms 8Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Kidney Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Breast Neoplasms 7Head and Neck Neoplasms 6Skin Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5

Interventions

Rituximab 6ibrutinib 4venetoclax 3acalabrutinib 3zanubrutinib 2pirtobrutinib 2fludarabine phosphate 2Whole-Body Irradiation 2Sirolimus 2Mycophenolic Acid 2Melphalan 2Cyclophosphamide 2Bortezomib 2Bendamustine Hydrochloride 2selinexor 1loncastuximab tesirine 1ixazomib 1carfilzomib 1Valganciclovir 1Valacyclovir 1Therapeutics 1Tacrolimus 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Lenalidomide 1Ganciclovir 1Foscarnet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Waldenstrom Macroglobulinemia × Nivolumab × Clear all
NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Active not recruiting
36 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡